galactose has been researched along with tamoxifen in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balar, DB; Patel, DD; Patel, MM; Patel, PS; Raval, GN; Rawal, RM | 1 |
| Bhatia, A; Bhushan, S; Katare, OP; Singh, B | 1 |
| Abdellatif, KRA; Abo El-Ela, FI; F, AG; Kharshoum, RM; Salem, HF | 1 |
3 other study(ies) available for galactose and tamoxifen
| Article | Year |
|---|---|
Seromucoid fraction: a useful biomarker for patients with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Breast Diseases; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Disease-Free Survival; Female; Hexoses; Humans; Middle Aged; Neoplasm Recurrence, Local; Orosomucoid; Postoperative Period; ROC Curve; Tamoxifen | 1998 |
Tamoxifen-encapsulated vesicular systems: cytotoxicity evaluation in human epidermal keratinocyte cell line.
Topics: Administration, Cutaneous; Cell Line; Cell Proliferation; Cell Survival; Cholesterol; Drug Carriers; Hexoses; Humans; Inhibitory Concentration 50; Keratinocytes; Liposomes; Membrane Fluidity; Phosphatidylcholines; Psoriasis; Selective Estrogen Receptor Modulators; Surface-Active Agents; Tamoxifen | 2010 |
Evaluation and optimization of pH-responsive niosomes as a carrier for efficient treatment of breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Cholesterol; Delayed-Action Preparations; Drug Liberation; Female; Gold; Hexoses; Hydrogen-Ion Concentration; Liposomes; Metal Nanoparticles; Mice; Tamoxifen; Tissue Distribution | 2018 |